TABLE 4.
Antiserum or antibody | No. of dissected intacta
: |
||
---|---|---|---|
MG | TSG | PSG | |
No-antibody control | 64 | 22 | 25 |
Cyclophilin preimmune serum | 47 | 10 | 21 |
Enolase preimmune serum | 29 | 13 | 10 |
CP-V preimmune serum | 38 | 13 | 18 |
EndoCP-GN preimmune serum | 11 | 2 | 7 |
EndoCP-V preimmune serum | 28 | 12 | 10 |
Anti-cyclophilin antibody | 26 | 15 | 10 |
Anti-enolase antibody | 58 | 25 | 21 |
Anti-CP-V antibody | 35 | 6 | 11 |
Anti-endoCP-GN antibody | 91 | 32 | 35 |
Anti-endoCP-V antibody | 50 | 20 | 20 |
Anti-mATPase antibody | 35 | 16 | 25 |
MG, midgut; TSG, tubular salivary gland; PSG, principal salivary gland.